Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2021 | Carbidopa/levodopa enteral suspension for PD

Gian Pal, MD, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, discusses non-neurosurgical interventions for Parkinson’s disease (PD). A combination of carbidopa and levodopa in a gel delivered directly into the intestines is currently available to treat the motor symptoms of PD. This strategy may be an alternative to help with motor fluctuations in patients who are not candidates for deep brain stimulation (DBS). However, the enteral suspension cannot reduce the medication burden to the same extent as DBS, and device maintenance must be considered. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.

Disclosures

•Dr. Pal has received personal compensation for serving as a Consultant for Guidepoint
•Dr. Pal has received personal compensation for serving on a Speakers Bureau for Sanofi
•The institution of Dr. Pal has received research support from National Institutes of Health
•The institution of Dr. Pal has received research support from Parkinson’s Foundation